Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 3Thoracic 1Sarcoma 1Plasma cell 1Dermatologic 1

Conditions

Small Cell Lung Carcinoma 1

Interventions

Cisplatin 71Carboplatin 68Paclitaxel 57Radiotherapy 43Specimen Handling 37Gemcitabine 36Erlotinib Hydrochloride 32Etoposide 30Magnetic Resonance Spectroscopy 29Docetaxel 28Taxes 27Pemetrexed 23Platinum 20Vinorelbine 191,2-diaminocyclohexaneplatinum II citrate 19Bevacizumab 18Cyclophosphamide 16Biopsy 16Radiation 15pembrolizumab 14Immunoglobulin G 12Disulfides 12Topotecan 11Gefitinib 11durvalumab 9atezolizumab 9aldesleukin 9Nivolumab 9Irinotecan 9Bortezomib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × obatoclax × Thoracic × Clear all
NCT00521144 2015-05-05

Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Completed
22 enrolled 9 charts
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡